Objective: To identify the major aggrecanase and matrix metalloproteinase (MMP) generated aggrecan fragments in human osteoarthritis (OA) synovial fluid and in human OA joint cartilage.
Introduction
The gradual destruction of joint cartilage is a prominent feature of OA, involving loss from the tissue of the major matrix components type II collagen and aggrecan. Aggrecan depletion in arthritic joints is largely due to fragmentation of the core protein by proteolysis. The involvement of aggrecanase in this process in human arthritis was first shown by the identification in human -being the predominant MMP cleavage site [4] [5] [6] [7] . One MMP cleavage site has been identified between the G2 domain and the keratan sulfate enriched region (KS) 8 , together with several sites in the chondroitin sulfate enriched region one (CS1) 9 . Several aggrecanase cleavage sites have been identified in the aggrecan core protein: one in the IGD [10] [11] [12] at Glu 373 -Ala 374 , other sites are located in the chondroitin sulfate enriched region two (CS2) 10, 11 .
Only a limited number of studies have used human synovial fluid 1, 2, 6, 13, 14 and human joint cartilage 4, 6, 14, 15 to characterize the aggrecan fragments generated in OA. While much of the current data suggest that destructive aggrecanolysis (i.e. in IGD) is due to aggrecanase activity 1, 2, 6, 14 , with ADAMTS-5 playing a lead role in mouse cartilage 16, 17 , other studies suggest that variable but quantitatively not well determined proportions of the IGD cleavage may be due to activity of MMP or other proteases 13, 15 . Further, deletion of the ADAMTS-5 catalytic domain in α The superscript numbers denote the amino acid residue positions. Human aggrecan residue numbers used in this paper were obtained by subtraction of 19 amino acids (leader sequence) from the total (1-2415 amino acid) sequence of human aggrecan (NCBI accession nr P16112 3 ).
genetically modified mice provided a partial but not complete protection against cartilage destruction and aggrecan loss in OA and arthritis models 16, 17 . A better understanding of the relative roles of the different proteolytic pathways is highly relevant for current efforts to develop disease-modifying treatments for human OA.
In the present study, we have identified aggrecan fragments in pooled human OA cartilage and in pooled OA human synovial fluid from a large number of patients with varying stages of OA. A well-characterized set of antibodies was used to detect and quantify both aggrecanase-and MMP-generated aggrecan fragments. We detect for the first time in human samples large glycosaminoglycan containing fragments with an MMP-generated N-terminus of 342 FFGV-both in OA synovial fluid and OA cartilage, and propose mechanisms for aggrecan degradation in human knee OA that incorporate the identified degradation patterns. from the human synovial fluid pool, using the same method and the same starting density. Both the associative and the dissociative preparations were conducted either in the absence or in the presence of proteinase inhibitors, 10 mM Na 4 -EDTA, 0.4 mM AEBSF, 1 µM Pepstatin A, 5 µM E64 and 5 mM o-phenathroline (in gradient centrifugation) and 10 mM Na 4 -EDTA, 0.4 mM PMSF, 1 µM Pepstatin A, 100 µM Iodoacetamide and 2 mM o-phenathroline (in dialysis).
Materials and Methods

MATERIALS
AGGRECAN ISOLATION FROM CARTILAGE
Aggrecan from a knee cartilage pool of ten OA patients was extracted with guanidine-HCl (4 M) in the presence of proteinase inhibitors (10 mM Na 4 -EDTA, 100 mM EACA, 10 mM NEM, 5 mM Benzamidine-HCl and 5 mM PMSF) and then isolated by associative-dissociative
CsCl density gradient centrifugation, in the presence of the proteinase inhibitors, as described 15 .
No hyaluronan (HA) was added. LGQR (1:500 or 1:1000 dilution), anti-TEGE (1:3000 dilution), anti-IPEN (1:10 000 dilution),
anti-ARGS (1:4000 dilution, 2.7 µg/ml), anti-SELE (1:1000 dilution, 1.2 µg/ml), anti-G1 (1:2000 or 1:5000 dilution, anti-G3 (1:500 dilution) and anti-CS stubs (1:3000 dilution). The following secondary peroxidase conjugated antibodies were used; goat anti-mouse IgG (1:50 000 and 1:15 000 dilutions, 2.5 or 0.75 ng/ml), goat anti-rabbit IgG (1:400 000 and 1:75 000 dilutions 2.5 or 13.3 ng/ml) and goat anti-mouse IgM (1:100 000 dilution). In the peptide blocking experiments the peptide and the antibody were incubated simultaneously with the blotted proteins.
QUANTIFICATION OF FFGV-AND ARGS-FRAGMENTS
The complete conversion of GAG containing G1-fragments to either FFGV-or ARGSfragments (with corresponding G1-IPEN and G1-TEGE fragments) was achieved by digesting (as described above) cartilage A1D1-fraction for 16h with MMP-3 or by digesting for 24h with ADAMTS-4. These samples were deglycosylated and used as FFGV-or ARGS-standards in the Western-blot quantification. The standards were assumed to contain one nmol FFGV-or ARGSfragments per mg aggrecan dry weight, using a Mw of 1x10 6 g/mol aggrecan. The synovial fluid sample (D1-fraction) and standards were probed by anti-ARGS or anti-FFGV antibodies as described above. The detection and quantification was conducted in a luminescence image analyzer (Fujifilm LAS-1000) using Image Gauge version 4.0 (Fujifilm) soft ware. Samples and standards were used within a linear range of the imaging system, and the total sum of FFGV-or ARGS-immuno-signal was used in the quantification.
IDENTIFICATION OF AGGRECAN FRAGMENTS IN SYNOVIAL FLUID AND CARTILAGE
Most of the CsCl-purified aggrecan fragments were immuno-identified at both N-and Cterminal ends. Fragments that were not immuno-verified at both ends were further characterized by molecular weight calculations, based on their migration in the PAGE-system, together with a specific calibration constant (A Struglics, S Larsson, LS Lohmander unpublished). The calibration constant (K) was generated from several aggrecan fragments identified at both N-and C-terminal ends by dividing the SDS-PAGE Mw (m) with the sum of the total amino acid Mw (a) and the total Mw of GAG stubs (g): K = m/(a + g).
Results
CHARACTERIZATION OF ANTIBODIES USING IN VITRO DIGESTED CARTILAGE AGGRECAN AND BLOCKING PEPTIDES
Several aggrecan fragments were detected in the ADAMTS-4 and MMP-3 in vitro digested cartilage-A1D1 samples (Fig. 2) . The N-and C-terminal sequences of these aggrecan fragments were determined in matching Western immuno-blot experiments ( Table I ). The anti-ARGS, anti-SELE, anti-KEEE and anti-FFGV neoepitope antibody immuno-reactions were completely blocked by the specific neoepitope peptides ( Fig. 2A-D) . Little or no blocking of the neoepitope immuno-reactions was observed in the presence of the corresponding spanning peptides ( Fig. 2A-D) . The anti-G1 immuno-reactions were completely blocked by the corresponding immunization peptide (Fig. 2E ), and this antibody has been further described 20, 21 .
The anti-ARGS antibody (mab OA1) has been further characterized by Western and ELISA experiments (Pratta et al. unpublished) , whereas characterization of anti-TEGE and anti-IPEN neoepitope antibodies was published 22 .
Peptide crossover experiments were conducted, testing e.g. anti-SELE immuno-reaction in the presence of ARGSVIL-peptide. None of these experiments showed false positive immunoblocking (results not shown).
The HRP conjugated secondary antibodies used in this paper did not bind directly to the blotted proteins in our Western immuno-blot experiment systems (results not shown). Further, the neoepitope antibodies used did not bind to human IgG, BSA, MMP-3, ADAMTS-4, deglycosylation enzymes or molecular weight markers (results not shown). The anti-G1 antibody showed immuno-reactivity against a 100 kDa non-aggrecan polypeptide which is marked as # in These findings show that the antibodies used were specific for the neoepitopes and sequences examined.
THE EFFECT OF PROTEINASE INHIBITORS DURING THE PURIFICATION AND DIALYSIS OF AGGRECAN
It was reported that guanidine-HCl denatured MMPs could be activated during dialysis against distilled water 23 . Therefore, we compared aggrecan purification from human synovial fluid and cartilage in the presence or absence of proteinase inhibitors (a) in the dialysis against showed similar molecular weights (Table I) . A difference observed in these comparison experiments was that the ADAMTS-4 in vitro digested cartilage-A1D1 sample contained a low molecular weight (51 kDa) anti-KEEE fragment, most likely 1546 GRGT-KEEE 1714 , which is not seen in the synovial fluid D1-fraction (Fig. 3 ), although this fragment was observed in other preparations of the OA synovial fluid D1-fraction (results not shown). In contrast, the aggrecan fragment pattern of the OA synovial fluid sample differed significantly from the aggrecan fragment pattern of MMP-3 in vitro digested cartilage-A1D1 and from the cartilage-A1D1 sample (Table I) .
These results suggest that the majority of the aggrecan fragments identified in human OA synovial fluid are generated from in vivo aggrecanase activity.
AGGRECAN FRAGMENTS DETECTED IN HUMAN OA SYNOVIAL FLUID ARE GENERATED FROM BOTH AGGRECANASE AND MMP ACTIVITIES
GAG-containing aggrecan fragments in the OA synovial fluid (D1-fraction) were identified in Western immuno-blot experiments by using anti-G1 and neoepitope antibodies (Fig.   4 ). To determine the likely N-and C-terminal sequences of the aggrecan fragments, several approaches were used. Firstly, the Western immuno-blot experiments were repeated several times with the different antibodies to give average values for the molecular weights of the aggrecan fragments. Secondly, the lanes on the PVDF-membranes were divided in half after transfer, incubated with different antibodies, and physically realigned before detection.
The neoepitope antibodies verified both aggrecanase and MMP generated N-terminal fragments in the OA synovial fluid (Fig. 4) . Several G1-domain containing fragments including ISGL (see Fig. 1 ). Table I ). This fragment has previously been detected in normal human synovial fluids 14 .
The 1920 LGQR-G3 fragment detected in SF-D1 samples was N-terminally ( Fig. 3) and Cterminally (result not shown) verified, and except for the C-terminals in 374 ARGS-and G1-CS1 971-1352 fragments and the N-terminal of the G1-KEEE 1714 fragment, all the high molecular weight SF-D1 fragments detected were immuno-verified both N-and C-terminally (Fig. 4) .
These results show that OA synovial fluid contains at least nine different GAG-containing aggrecanase and MMP generated fragments. Several of these fragments were likely produced by (Fig. 6 and Table I ). In addition, several high molecular weight G1 fragments were observed in the cartilage-A1D1 sample. Besides the 429 kDa full length G1-G3 molecule (also verified C-terminally, results not shown), the cartilage-A1D1 sample also contained a 367 kDa G1-KEEE 1714 fragment, a 331 kDa G1-SELE 1545 fragment and two (197 and 217 kDa) G1-GVED 971-1352 (-CS1) fragments ( Fig. 6 and Table I ). The 100 kDa false-positive anti-G1 immuno-band, derived from chondroitinase ABC polypeptide ( Fig. 2) , was also observed in the cartilage-A1D1 sample (Fig. 6 ). No N-terminal
LGQR fragments were observed in these cartilage samples (results not shown).
These results show that several high molecular weight GAG containing fragments with Nterminal sequences of either G1-or 342 FFGV-, but not 374 ARGS-, are present in the OA cartilage.
FFGV-AND ARGS-FRAGMENTS WERE QUANTIFIED IN HUMAN OA SYNOVIAL FLUID
OA synovial fluid (D1-fraction) was quantified for content of FFGV-or ARGS-fragments using FFGV-and ARGS-standards, generated by MMP-3 or ADAMTS-4 total aggrecan cartilage-A1D1 digests (as an example see Fig. 2A and 2D ), using Western immuno-blot and a luminescence imaging system. The OA synovial fluid contained 40.3 pmol FFGV-and 107 pmol ARGS-fragments per ml neat synovial fluid, with an ARGS-to FFGV-fragment molar ratio of 2.7 (Table II) . The GAG concentration in the human synovial fluid pool was 140 µg per ml.
Based on the assumption that 75 % of the aggrecan Mw represents GAG, the total amount of aggrecan fragments per ml SF was 185 µg, or 185 pmoles assuming an Mw for aggrecan of 1x10 6 g/mol. Based on this quantification, 20-25% of the GAG-containing aggrecan fragments in pooled human OA synovial fluid carried the FFGV-N-terminal sequence, while the corresponding proportion carrying the ARGS-terminal was 55-60%.
Discussion
Our understanding of aggrecan degradation pathways in vivo in human OA is based on samples from a small number of patients 1, 2, 6, 13, 14 . By pooling synovial fluids from more than a hundred OA patients, we have identified the major aggrecan fragments present in knee OA synovial fluid, independent of disease stage, age, and other variables that might influence fragment patterns in the individual patient. Due to ethical constraints the human joint cartilage used was limited to that from knee replacement surgery, and subject origin was separate from the origin of the synovial fluid pool. However, the joint cartilage pool included a range of samples from the macroscopically normal to that with advanced OA pathology. The OA synovial fluid results presented in this paper were obtained from several D1-and A1-fraction preparations, and the OA cartilage data were obtained from two separate A1D1/A1D3 preparations, all providing reproducible results. Using Western immunoblot, we detected no differences in the aggrecan fragment patterns or intensities of cartilage and synovial fluid samples when the purification was done in the presence or absence of proteinase inhibitors. This contrasts to a previous report, where aggrecanolysis by MMPs was observed during the dialysis step in the absence of proteinase inhibitors when guanidine-HCl was removed from extracts of cultured pig cartilage 23 .
However, the cartilage explants used in that study were stimulated in vitro with IL-1, which would be expected to significantly upregulate protease expression and activity.
All the antibodies used were carefully tested for false positive recognition. We characterized the aggrecan fragments by identification of both N-and C-terminal sequences using
Western immuno-blot and by size calculation based on electrophoretic migration.
Although the OA synovial fluid contained several aggrecan fragments generated by both aggrecanases and MMPs, and some that were generated only by MMP (Table I) , it is evident from the Western immuno-blots that the aggrecan fragment pattern in OA synovial fluid was mainly generated by aggrecanase activity ( Fig. 3 ; Table I ). It has been suggested that ADAMTS- 25 . At the protease concentrations used in the present study we were unable to replicate these findings (Table I ).
The differential distribution of aggrecan fragments between OA cartilage and OA synovial fluid (Table I , Fig. 7 ) may be caused by several different, but not mutually exclusive, processes, including but not limited to those discussed here. Firstly, aggrecan structure is variable. For example, newly synthesized molecules are likely to have an intact G3 domain while older aggrecan molecules appear to be increasingly truncated at the C-terminal end. This heterogeneity of the aggrecan core protein will influence the behavior of fragments once cleaved, for example through interaction of the G3 domain with other matrix components 26 . Further, variability of aggrecan carbohydrate substitution may affect protease susceptibility 27 . It is unclear to what extent aggregation varies, but this may also influence aggrecan fragment behavior.
Secondly, with more than one protease involved in degradation, there is potential for differential protease activation and substrate specificity, the latter influenced by the order of cleavage.
Further potential for variability in aggrecan degradation pathways may be provided by C-terminal processing of ADAMTS-4 which was shown to influence its binding to extracellular matrix components, and substrate specificity 28 . ADAMTS-4 is inhibited by TIMP-3 and by interaction with fibronectin, providing yet other possibilities for protease regulation 29, 30 . Thirdly, the differential distribution of aggrecan subpopulations and proteolytic activities within the cartilage matrix and synovial fluid will likely play an important role in generating the observed distribution. For example, molecules of different ages may be differentially distributed within the cartilage matrix, and newly synthesized molecules with an intact G3 domain may be preferentially located close to the chondrocytes in the territorial matrix, while older, truncated molecules may dominate in the interterritorial matrix. Fourthly, cellular uptake mechanisms may differentiate between different molecular fragments.
Since we detected in human OA cartilage both aggrecanase-generated G1-TEGE 373 and MMP-generated G1-IPEN 341 fragments (Fig. 5) , their distal counterparts, carrying the neoepitopes 374 ARGS-and 342 FFGV-, must both have been produced in the tissue. There was, however, a striking difference in the distribution of these fragments between cartilage and synovial fluid. The MMP-generated 342 FFGV-fragments were partly retained in cartilage (Tables   I, II; Figs. 6, 7), whereas the aggrecanase generated 374 ARGS-fragments were not found in the tissue but only in the synovial fluid (Table I; Figs. 4A, 6, 7). Quantification showed that the OA synovial fluid pool contained 107 pmoles per ml of 374 ARGS-fragments (Table II) . This amount corresponds to approximately 60 % of the total amount of aggrecan fragments in human OA synovial fluid (estimated to 185 pmoles/ml), and corroborates earlier findings in arthritic synovial fluids 1, 2 .
Although the possibility exists that the 374 ARGS-fragments detected in the synovial fluid are the result of aggrecanase activity in the joint cavity, we suggest that these fragments are a product of aggrecanase cleavage of molecules within the cartilage that lack the G3-domain.
When such G3-truncated fragments are detached from the HA interacting G1-domain by aggrecanase cleavage, diffusion into the joint cavity may occur. Consistent with this proposal, all the 374 ARGS-fragments detected in the OA synovial fluid lacked the G3-domain (Figs. 4, 7) .
Cartilage explant experiments have shown that 374 ARGS-fragments readily migrate out into the culture media, resulting in very low 374 ARGS-neoepitope content in the tissue 6, 31 . On the other hand, a possible association between the KS enriched regions of aggrecan and type II collagen has been reported 32, 33 , which could act to retain these fragments in the cartilage. Endocytosis by chondrocytes of 374 ARGS-neoepitope fragments may also occur, although an HA-G1 complex is required for the endocytosis 34 .
The partial retention in the cartilage of the large 342 FFGV-G3 fragments (Figs. 6, 7) , where the G3 domain may interact with fibulin-2 and other matrix molecules 26 , could be explained if aggrecan molecules attacked by MMPs were preferentially those newly synthesized and still retaining their G3 domain. It is more difficult to explain the matrix retention of the G3-truncated FFGV-fragments 342 FFGV-CS1 and 342 FFGV-KEEE 1714 (Fig. 6 ). Since 374 ARGSfragments of similar sizes are detected in synovial fluid, but not in the cartilage (Table I; (Table I) , which indicates an association between these fragments and HA or other molecules binding to HA. Partial matrix retention of G3-truncated 342 FFGV-fragments has been reported 37 . Previously detected FFGV fragments in human OA synovial fluid 13, 38 and in porcine cartilage 37 were a mixture of several smaller peptides ranging between 40-200 kDa. In contrast,
we detected large (> 300 kDa) 342 FFGV-aggrecan fragments in the OA synovial fluid and OA cartilage (Figs. 4B, 6 ). The level of the large 342 FFGV-aggrecan fragments in the OA synovial fluid pool was about 40 pmol per ml, or 20-25% of the total amount of aggrecan fragments (Table II) . This compares with previous findings of 10-20 pmol per ml OA synovial fluid, where a competitive ELISA using the FFGV epitope mab AF28 was used to detect low Mw FFGVfragments 13 .
We readily detected both G1-TEGE 373 and G1-IPEN 341 fragments in OA cartilage (Fig.   5 ), similar to previous reports using Western analysis 6, 14, 15 or immunohistochemistry 15 .
However, we detected insignificant amounts of G1-IPEN 341 fragments in the OA synovial fluid with anti-G1 or anti-IPEN antibodies, while G1-TEGE 373 was readily detected with both anti-G1
and anti-TEGE antibodies. Even though the sensitivity and affinity of the anti-TEGE and anti-
IPEN neoepitope antibodies may differ, these results together with the results based on anti-G1
Western analysis show that there were insignificant amounts of G1-IPEN 341 fragments in the OA synovial fluid pool as compared to the OA cartilage pool (Fig. 5) . This contrasts to other reports that have detected both -TEGE 373 and -IPEN 341 neoepitopes in some individual OA synovial fluid samples, although the quantity of the -TEGE 373 neoepitope was greater 14 .
There 
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